EFS and OS of patients with previously untreated MM with IGF-1R^absent or IGF-1R^present MMCs and with IL-6R^low and IL-6R^high MMCs.IGF-1R and IL-6R expression was assayed in purified MMCs with Affymetrix U133 microarrays. Patients from Heidelberg or Montpellier hospitals (HM series) were treated with high-dose chemotherapy and autologous stem cell transplantation. A total of 118 patients had IGF-1R^absent MMCs and 53 IGF-1R^present MMCs, and 85 patients had IL-6R^low MMCs and 85 IL-6R^high MMCs. We used also patient data from the Arkansas-Little Rock group (GEO accession number GSE2658). These patients from the Arkansas group were treated with total therapy 2 and termed for convenience LR-TT2 series. A total of 114 patients had IGF-1R^absent MMCs and 136 IGF-1R^present MMCs, and 172 patients had IL-6R^low MMCs and 172 IL-6R^high MMCs. EFS of IGF-1R^absent MMCs and IGF-1R^present MMCs patients from HM series (A) and from LR-TT2 series (B). OS of IGF-1R^absent MMC and IGF-1R^present MMC patients from the HM series (C) and from the LR-TT2 series (D). The P value was determined with a log-rank test. EFS of IL-6R^low MMC and IL-6R^high MMC patients from the HM series (E) and from the LR-TT2 series (F). OS IL-6R^low MMC and IL-6R^high MMC patients from the HM series (G) and from the LR-TT2 series (H). The P value was determined with a log-rank test.